hy 163731 Search Results


egr1 inhibitor  (MedChemExpress)
94
MedChemExpress egr1 inhibitor
a ChIP-Seq profiles from ENCODE database identified a potential binding site for early growth response 1 <t>(EGR1)</t> in DPEP2 promoter region. b EGR1 is an inflammation-inducible transcriptional repressor responsible for suppressing DPEP2 expression in macrophages during sepsis. This image was created in BioRender. Qiu, Z. (2026) https://biorender.com/t7mfnvo . c Levels of Egr1 were determined after LPS stimulation for 0 or 12 h in RAW264.7 cells ( n = 3 biological replicates). d The expression of Dpep2 of RAW264.7 cells pre-treated with an inhibitor targeting EGR1 for 0 or 1 h, followed by LPS stimulation for 0 or 12 h, were determined ( n = 3 biological replicates). e Levels of Dpep2 were determined after LPS stimulation for 0 or 12 h in RAW264.7 cells with Egr1 deficiency (sh Egr1 ) vs control RAW264.7 cells (shNT) ( n = 3 biological replicates). f Cysteine leukotrienes and prostaglandin E2 (PGE2) synthesis pathways. g – j Levels of leukotriene D4 (LTD4) and leukotriene E4 (LTE4) secreted by RAW264.7 cells with Dpep2 deficiency (sh Dpep2 RAW264.7 cells) vs control RAW264.7 cells (shNT RAW264.7 cells) ( g , h ), and RAW264.7 cells overexpressing Dpep2 (DPEP2) vs control vector (Vector) cells ( i , j ) ( n = 3 biological replicates). k RAW264.7 cells were treated with 1 μg/mL LPS + 1 μM LTD4, or 1 μg/mL LPS + 1 μM LTE4, or 1 μg/mL LPS + DMSO for 12 h. Then, levels of Il1b , Il6, and Tnf were determined ( n = 3 biological replicates). l Flag-tagged WT DPEP2 plasmid and the enzymatic mutant targeting E190 (E190Q) were constructed. m RAW264.7 cells overexpressing WT DPEP2 (WT), enzymatic mutant DPEP2 and relatively control (Vector) were constructed. Protein levels of Flag in these cells were examined ( n = 3 or 6 biological replicates). n, o ELISA was used to measure LTD4 and LTE4 levels secreted by Vector, WT, and E190Q cells ( n = 3 biological replicates). p–r Il1b , Il6, and Tnf levels in Vector, WT, and E190Q cells were measured by quantitative real-time PCR after 12h of LPS stimulation (n=3 biological replicates). Data represent the mean ± standard deviation. ns, not significant. Two-sided unpaired Student’s t test was used in ( c ), one way ANOVA followed by the Bonferroni multiple comparisons was used in ( d, e, k, m–r ) and two-way repeated measures ANOVA with Tukey’s multiple comparisons test was used in ( g–j ).
Egr1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy+163731/EGR-1-IN-1/pmc13103307-375-6-13
Average 94 stars, based on 1 article reviews
egr1 inhibitor - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


a ChIP-Seq profiles from ENCODE database identified a potential binding site for early growth response 1 (EGR1) in DPEP2 promoter region. b EGR1 is an inflammation-inducible transcriptional repressor responsible for suppressing DPEP2 expression in macrophages during sepsis. This image was created in BioRender. Qiu, Z. (2026) https://biorender.com/t7mfnvo . c Levels of Egr1 were determined after LPS stimulation for 0 or 12 h in RAW264.7 cells ( n = 3 biological replicates). d The expression of Dpep2 of RAW264.7 cells pre-treated with an inhibitor targeting EGR1 for 0 or 1 h, followed by LPS stimulation for 0 or 12 h, were determined ( n = 3 biological replicates). e Levels of Dpep2 were determined after LPS stimulation for 0 or 12 h in RAW264.7 cells with Egr1 deficiency (sh Egr1 ) vs control RAW264.7 cells (shNT) ( n = 3 biological replicates). f Cysteine leukotrienes and prostaglandin E2 (PGE2) synthesis pathways. g – j Levels of leukotriene D4 (LTD4) and leukotriene E4 (LTE4) secreted by RAW264.7 cells with Dpep2 deficiency (sh Dpep2 RAW264.7 cells) vs control RAW264.7 cells (shNT RAW264.7 cells) ( g , h ), and RAW264.7 cells overexpressing Dpep2 (DPEP2) vs control vector (Vector) cells ( i , j ) ( n = 3 biological replicates). k RAW264.7 cells were treated with 1 μg/mL LPS + 1 μM LTD4, or 1 μg/mL LPS + 1 μM LTE4, or 1 μg/mL LPS + DMSO for 12 h. Then, levels of Il1b , Il6, and Tnf were determined ( n = 3 biological replicates). l Flag-tagged WT DPEP2 plasmid and the enzymatic mutant targeting E190 (E190Q) were constructed. m RAW264.7 cells overexpressing WT DPEP2 (WT), enzymatic mutant DPEP2 and relatively control (Vector) were constructed. Protein levels of Flag in these cells were examined ( n = 3 or 6 biological replicates). n, o ELISA was used to measure LTD4 and LTE4 levels secreted by Vector, WT, and E190Q cells ( n = 3 biological replicates). p–r Il1b , Il6, and Tnf levels in Vector, WT, and E190Q cells were measured by quantitative real-time PCR after 12h of LPS stimulation (n=3 biological replicates). Data represent the mean ± standard deviation. ns, not significant. Two-sided unpaired Student’s t test was used in ( c ), one way ANOVA followed by the Bonferroni multiple comparisons was used in ( d, e, k, m–r ) and two-way repeated measures ANOVA with Tukey’s multiple comparisons test was used in ( g–j ).

Journal: Nature Communications

Article Title: DPEP2 suppresses hyperinflammation via metabolic reprogramming of macrophages in sepsis

doi: 10.1038/s41467-026-70466-4

Figure Lengend Snippet: a ChIP-Seq profiles from ENCODE database identified a potential binding site for early growth response 1 (EGR1) in DPEP2 promoter region. b EGR1 is an inflammation-inducible transcriptional repressor responsible for suppressing DPEP2 expression in macrophages during sepsis. This image was created in BioRender. Qiu, Z. (2026) https://biorender.com/t7mfnvo . c Levels of Egr1 were determined after LPS stimulation for 0 or 12 h in RAW264.7 cells ( n = 3 biological replicates). d The expression of Dpep2 of RAW264.7 cells pre-treated with an inhibitor targeting EGR1 for 0 or 1 h, followed by LPS stimulation for 0 or 12 h, were determined ( n = 3 biological replicates). e Levels of Dpep2 were determined after LPS stimulation for 0 or 12 h in RAW264.7 cells with Egr1 deficiency (sh Egr1 ) vs control RAW264.7 cells (shNT) ( n = 3 biological replicates). f Cysteine leukotrienes and prostaglandin E2 (PGE2) synthesis pathways. g – j Levels of leukotriene D4 (LTD4) and leukotriene E4 (LTE4) secreted by RAW264.7 cells with Dpep2 deficiency (sh Dpep2 RAW264.7 cells) vs control RAW264.7 cells (shNT RAW264.7 cells) ( g , h ), and RAW264.7 cells overexpressing Dpep2 (DPEP2) vs control vector (Vector) cells ( i , j ) ( n = 3 biological replicates). k RAW264.7 cells were treated with 1 μg/mL LPS + 1 μM LTD4, or 1 μg/mL LPS + 1 μM LTE4, or 1 μg/mL LPS + DMSO for 12 h. Then, levels of Il1b , Il6, and Tnf were determined ( n = 3 biological replicates). l Flag-tagged WT DPEP2 plasmid and the enzymatic mutant targeting E190 (E190Q) were constructed. m RAW264.7 cells overexpressing WT DPEP2 (WT), enzymatic mutant DPEP2 and relatively control (Vector) were constructed. Protein levels of Flag in these cells were examined ( n = 3 or 6 biological replicates). n, o ELISA was used to measure LTD4 and LTE4 levels secreted by Vector, WT, and E190Q cells ( n = 3 biological replicates). p–r Il1b , Il6, and Tnf levels in Vector, WT, and E190Q cells were measured by quantitative real-time PCR after 12h of LPS stimulation (n=3 biological replicates). Data represent the mean ± standard deviation. ns, not significant. Two-sided unpaired Student’s t test was used in ( c ), one way ANOVA followed by the Bonferroni multiple comparisons was used in ( d, e, k, m–r ) and two-way repeated measures ANOVA with Tukey’s multiple comparisons test was used in ( g–j ).

Article Snippet: RAW264.7 cells were treated with a EGR1 inhibitor (5 μM EGR-1-IN-1 (IT25); HY-163731, MedChemExpress), CysLTR1 inhibitor (5 μM Zafrilukast; HY-17492, MedChemExpress), CysLTR2 inhibitor (1 μM HAMI3379; HY-112248A MedChemExpress), NF-κB inhibitor (30 μM JSH-23; HY-13982, MedChemExpress), ERK inhibitor (1 μM U0126; HY-12031A, MedChemExpress), JNK inhibitor (25 μM SP600125; HY-12041, MedChemExpress), p38 MAPK inhibitor (30 μM SB203580; HY-10256, MedChemExpress), or AKT inhibitor (30 μM Ly294002; HY-10108, MedChemExpress), for 1 h and stimulated with LPS (1 μg/mL) for 12 h.

Techniques: ChIP-sequencing, Binding Assay, Expressing, Control, Plasmid Preparation, Mutagenesis, Construct, Enzyme-linked Immunosorbent Assay, Real-time Polymerase Chain Reaction, Standard Deviation